Non-invasive prenatal testing leading to a maternal diagnosis of Charcot–Marie–Tooth neuropathy

4Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Non-invasive prenatal testing (NIPT) is increasingly used in routine practice due to its high sensitivity and specificity in detecting fetal chromosomal anomalies. Several reports have highlighted that NIPT can diagnose previously unsuspected malignancy or benign copy number variation in the expectant mother. We report a case in which NIPT detected a duplication involving the 17p11.2-17p12 region with possible Potocki–Lupski syndrome in the fetus. However, on further questioning, the mother revealed that she had Charcot–Marie–Tooth neuropathy type IA (CMT1A) and thus using array CGH, we were able to confirm that the 17p duplication was maternal in origin, included only the typical CMT1A region and that the fetus had a normal chromosome complement. Although it may be rare for a mother to have a pathogenic chromosome duplication/deletion, with the expansion in scope of NIPT from classic trisomies to global chromosome coverage and monogenic conditions, more examples of fortuitous maternal diagnosis will certainly be forthcoming and this should be taken into account during pre-test genetic counseling.

Cite

CITATION STYLE

APA

Kumps, C., Niel Bütschi, F., Rapin, B., Baud, D., Pescia, G., Robyr, D., … Unger, S. (2020). Non-invasive prenatal testing leading to a maternal diagnosis of Charcot–Marie–Tooth neuropathy. Journal of Human Genetics, 65(11), 1035–1038. https://doi.org/10.1038/s10038-020-0789-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free